Curve Therapeutics Announces Investment from co-lead Epidarex Capital

Southampton, UK, 31st July 2020. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces an investment of £2.25 Mn from Epidarex Capital, a trans-Atlantic venture capital firm that invests in early-stage, high growth life science and health technology companies in emerging and under-ventured research hubs within the UK and US. Epidarex joins Advent Life Sciences as co-lead in Curve’s seed round.

Curve originated from world-leading Microcycle® research conducted by Professor Tavassoli’s group in the Department of Chemistry at the University of Southampton, UK. The company is  pioneering a game-changing, functional, drug discovery engine to generate higher quality functional hits and leads with the aim of discovering first-in-class therapeutics against challenging therapeutic targets.